Korro Bio Inc (KRRO) Stock Price, Quote & News

Company Profile

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The c...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 468 1999

Website: www.korrobio.com

Address:

One Kendall Square, Building 600-700 Suite 6-401, Cambridge, United States

TalkMarkets Jan. 19 at 9:03 PM

January Bounce Follow-Up $ATYR $KRRO $NFE $PLRX $SEAT https://talkmarkets.com/content/stocks--equities/january-bounce-follow-up?post=551103

0 · Reply

Dizzy8 Jan. 16 at 1:32 PM

$KRRO Not in, but expecting this to fire up 🔥

0 · Reply

Estimize Jan. 15 at 12:42 PM

Wall St is expecting -2.03 EPS for $KRRO Q4 [Reporting 03/31 AMC] http://www.estimize.com/intro/krro?chart=historical&metric_name=eps&utm_c

0 · Reply

Crypto9999 Jan. 12 at 5:34 PM

$KRRO Dip buying before double digits..(imo) $20+++🧲🧲🧲🧲

0 · Reply

Struin Jan. 9 at 5:05 PM

$KRRO 10 comes soon

0 · Reply

Crypto9999 Jan. 9 at 4:18 PM

$KRRO Looking for double digits by COB today..... 💪 $20+++🧲🧲🧲🧲

0 · Reply

Struin Jan. 9 at 3:52 PM

$KRRO Soon $20 same as MLTX

0 · Reply

Crypto9999 Jan. 8 at 11:52 PM

$PFE In the spirit of M& Recent article: Big Pharma race to snap up biotech assets as $170 billion patent cliff looms... Less than 6 million shares in the float, a healthy patent repository... KRRO is poised(imo) for a massive run...

0 · Reply

FlyingChemist01 Jan. 8 at 10:32 PM

$KRRO $NVO

0 · Reply

Crypto9999 Jan. 8 at 6:28 PM

$KRRO This is a lonely message board.🤣 Actually, not a bad thing. Less awareness, until FOMO..🤑🤑 Double digits incoming...

0 · Reply

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 13, 2025, 2:26 PM EST - 2 months ago

Korro Bio Early Trial Results Fall Short; Stock Hits New Low

Nov 12, 2025, 5:59 PM EST - 2 months ago

This biotech is halting its work with Novo Nordisk and laying off more people

Nov 12, 2025, 4:05 PM EST - 2 months ago

Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs

Sep 2, 2025, 4:30 PM EDT - 4 months ago

Korro to Participate in Upcoming Investor and Scientific Conferences

Aug 12, 2025, 7:00 AM EDT - 5 months ago

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 21, 2025, 8:00 AM EDT - 6 months ago

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

May 14, 2025, 4:05 PM EDT - 8 months ago

Korro to Participate in Upcoming Investor Conferences

May 7, 2025, 4:30 PM EDT - 9 months ago

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 1, 2025, 7:30 AM EDT - 10 months ago

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

Mar 18, 2025, 7:00 AM EDT - 11 months ago

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

Mar 14, 2025, 8:00 AM EDT - 11 months ago

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

Feb 26, 2025, 8:00 AM EST - 11 months ago

Korro to Present at the TD Cowen 45th Annual Health Care Conference

Nov 21, 2024, 7:30 AM EST - 1 year ago

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Nov 14, 2024, 8:00 AM EST - 1 year ago

Korro to Present at the Jefferies London Healthcare Conference

Nov 4, 2024, 7:25 AM EST - 1 year ago

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Korro to Participate in Upcoming September Investor and Scientific Conferences

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

May 30, 2024, 4:01 PM EDT - 1 year ago

Korro to Participate in Upcoming June Investor and Scientific Conferences

May 20, 2024, 2:30 PM EDT - 1 year ago

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

May 14, 2024, 4:01 PM EDT - 1 year ago

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Korro Announces $70 Million Private Placement

Mar 26, 2024, 4:01 PM EDT - 1 year ago

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

Mar 14, 2024, 5:34 PM EDT - 2 years ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRYS MREO TAK WVE

Feb 27, 2024, 8:00 AM EST - 2 years ago

Korro to Present at the TD Cowen 44th Annual Health Care Conference

Jan 18, 2024, 8:00 AM EST - 2 years ago

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

Jan 4, 2024, 8:00 AM EST - 2 years ago

Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 7, 2023, 8:00 AM EST - 2 years ago

Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Nov 28, 2023, 8:00 AM EST - 2 years ago

Korro Bio Appoints Dr. Rachel Meyers to Board of Directors

Nov 3, 2023, 3:31 PM EDT - 2 years ago

UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Nov 3, 2023, 12:19 PM EDT - 2 years ago

Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Oct 6, 2023, 2:14 PM EDT - 2 years ago

FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ

Aug 10, 2023, 4:01 PM EDT - 2 years ago

Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results

Jul 14, 2023, 6:30 AM EDT - 2 years ago

Korro Bio and Frequency Therapeutics Announce Merger Agreement

May 12, 2023, 4:01 PM EDT - 2 years ago

Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results

Mar 10, 2023, 7:30 AM EST - 3 years ago

Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results

Feb 27, 2023, 7:30 AM EST - 3 years ago

Frequency Therapeutics to Participate at Upcoming March Investor Conferences

Feb 23, 2023, 7:45 AM EST - 3 years ago

Small Animal Imaging In Vivo Market is Anticipated to Reach a Value of USD 6.1 Billion by Growing at a CAGR of 8.89% During 2022-2028; Expanding Healthcare Sector and Rising Clinical Research to Elevate Market Growth

Feb 13, 2023, 8:05 AM EST - 3 years ago

Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Dec 19, 2022, 7:30 AM EST - 3 years ago

Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program

Dec 15, 2022, 7:30 AM EST - 3 years ago

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company's Second Therapeutic Candidate for Sensorineural Hearing Loss

Nov 17, 2022, 7:30 AM EST - 3 years ago

Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results

Nov 8, 2022, 4:05 PM EST - 3 years ago

Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results

Oct 12, 2022, 7:30 AM EDT - 3 years ago

Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Aug 30, 2022, 7:30 AM EDT - 3 years ago

Frequency Therapeutics to Participate in September Investor and Medical Conferences

Aug 9, 2022, 4:05 PM EDT - 3 years ago

Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results

TalkMarkets Jan. 19 at 9:03 PM

January Bounce Follow-Up $ATYR $KRRO $NFE $PLRX $SEAT https://talkmarkets.com/content/stocks--equities/january-bounce-follow-up?post=551103

0 · Reply

Dizzy8 Jan. 16 at 1:32 PM

$KRRO Not in, but expecting this to fire up 🔥

0 · Reply

Estimize Jan. 15 at 12:42 PM

Wall St is expecting -2.03 EPS for $KRRO Q4 [Reporting 03/31 AMC] http://www.estimize.com/intro/krro?chart=historical&metric_name=eps&utm_c

0 · Reply

Crypto9999 Jan. 12 at 5:34 PM

$KRRO Dip buying before double digits..(imo) $20+++🧲🧲🧲🧲

0 · Reply

Struin Jan. 9 at 5:05 PM

$KRRO 10 comes soon

0 · Reply

Crypto9999 Jan. 9 at 4:18 PM

$KRRO Looking for double digits by COB today..... 💪 $20+++🧲🧲🧲🧲

0 · Reply

Struin Jan. 9 at 3:52 PM

$KRRO Soon $20 same as MLTX

0 · Reply

Crypto9999 Jan. 8 at 11:52 PM

0 · Reply

FlyingChemist01 Jan. 8 at 10:32 PM

$KRRO $NVO

0 · Reply

Crypto9999 Jan. 8 at 6:28 PM

$KRRO This is a lonely message board.🤣 Actually, not a bad thing. Less awareness, until FOMO..🤑🤑 Double digits incoming...

0 · Reply

Crypto9999 Jan. 8 at 5:06 PM

$KRRO Need to knock down the small (roughly 5k shares) at 9.08. $10 by tomorrow? With their repository of patents,we could see an acquisition play... Recent article: Big Pharma race to snap up biotech assets as $170 billion patent cliff looms...

0 · Reply

Crypto9999 Jan. 8 at 4:38 PM

$KRRO November 12-13 the stock went down 25 dollars... Expecting a run here... Get in before the January 15th 44th Annual J.P. Morgan Healthcare Conference... Less than 6 million shares in the float..🚀🚀 $20++++🧲🧲🧲🧲

0 · Reply

hitmongreen Jan. 8 at 3:19 PM

$KRRO 🤞

0 · Reply

Estimize Dec. 31 at 9:00 PM

Wall St is expecting -2.03 EPS for $KRRO Q4 [Reporting 03/31 AMC] http://www.estimize.com/intro/krro?chart=historical&metric_name=eps&utm_c

0 · Reply

UgoGreg Dec. 30 at 10:44 PM

$KRRO https://youtu.be/pXFO9_cJJUM

0 · Reply

BullBobo Dec. 30 at 5:01 PM

$KRRO Time to load up another 50k

0 · Reply

SuperGreenToday Dec. 29 at 6:48 PM

$KRRO Share Price: $7.99 Contract Selected: Dec 18, 2026 $10 Calls Buy Zone: $2.45 – $3.02 Target Zone: $4.39 – $5.36 Potential Upside: 69% ROI Time to Expiration: 353 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

LogicLens Dec. 25 at 5:28 PM

$KRRO Macro forces may influence direction, yet internal execution remains the decisive factor. Execution gaps should narrow meaningfully over coming quarters. Evidence of resilience during turbulence would be constructive. Patience is reasonable — but it must be matched by tangible progress.

0 · Reply

BullBobo Dec. 24 at 3:41 PM

$KRRO ...in to the double digit soon !

0 · Reply

AdAgencyAce Dec. 24 at 11:17 AM

$KRRO Current positioning will be tested as progress validates the underlying thesis beyond narrative appeal. Long-term optimism depends on disciplined follow-through.

0 · Reply

UgoGreg Dec. 20 at 5:53 PM

$KRRO https://youtu.be/ygBN8MilTyc

0 · Reply

Crypto9999 Dec. 16 at 6:27 PM

$KRRO With approximately 5.2-5.7 million shares in the float and roughly 1,240,000 shares short or almost 25%.... One upgrade, positive news release, more institutional buys.... we're (imo) double digits quickly. Send those shorts packing... $20+++🧲🧲🧲🧲

0 · Reply

Market Cap	82.68M
Revenue (ttm)	2.27M
Net Income (ttm)	-83.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,681.94%
Debt to Equity Ratio	0.00

Volume	124,500
Avg Vol	583,730
Day's Range	N/A - N/A
Shares Out	9.42M
Stochastic %K	54%
Beta	2.95
Analysts	Hold
Price Target	$8.25